Skip to Main Content
Try STAT+ TODAY
Trending:
First Opinion
Biotech
Health
Coronavirus
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

With $11 billion Acceleron deal, new Merck CEO hopes to convince investors there is a lot more to the biopharma giant

  • Matthew Herper

By Matthew Herper Sept. 30, 2021

Reprints
Rob Davis
Merck CEO Rob Davis Merck

Merck will continue to search out more acquisitions after its $11 billion purchase of biotech firm Acceleron Pharma, the company’s CEO told STAT in an interview Thursday.

But the CEO, Rob Davis, said he also believes that investors have not yet come to realize the value of the experimental drugs Merck is developing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Matthew Herper

Matthew Herper

Senior Writer, Medicine, Editorial Director of Events

Matthew covers medical innovation — both its promise and its perils.

Tags

Create a display name to comment

This name will appear with your comment

The health insurer will see you now: How UnitedHealth…
The health insurer will see you now: How UnitedHealth is keeping more profits, as your doctor
‘A constant information lag’: The troubled recall of Philips…
‘A constant information lag’: The troubled recall of Philips CPAP machines underscores flaws in device oversight
Why doesn’t the U.S. have at-home flu tests?
Why doesn’t the U.S. have at-home flu tests?
Pharmalittle: J&J drops out of bidding for Horizon; FDA…
Pharmalittle: J&J drops out of bidding for Horizon; FDA takes a harder line on fast-track approvals
The health insurer will see you now: How UnitedHealth…
The health insurer will see you now: How UnitedHealth is keeping more profits, as your doctor
Thirty Madison, looking to stand out in a crowded…
Thirty Madison, looking to stand out in a crowded telehealth market, quietly plans expansion into sleep…

Recommended Stories